Higher-precision PRRT dosing versus standard dosing for NEN
Part of Cancer clinical trials.
This Phase 2 study compares a more personalized (precision) radiation dose plan to the standard dose plan using Lu-177-DOTATOC for people with neuroendocrine neoplasms (NEN) that have worsened or caused major symptoms despite usual treatments. The goal is to see if better planning can improve treatment delivery while staying safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to give informed consent
- Have NEN confirmed on tissue biopsy (histology)
- Have disease that is progressing despite standard treatments (or you cannot tolerate them, or symptoms are not controlled)
- Have an average day-to-day functioning score of 0 to 2 (performance status)
- Have enough kidney and bone marrow function based on blood tests and kidney clearance results
- Have a scan showing the cancer takes up Ga-DOTATOC more than the liver (or get a new scan if yours is older than 3 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining peptide receptor radionuclide therapy (PRRT) with long-acting somatostatin analogues to see how much radiation reaches the tumor. It is for people with neuroendocrine tumors who meet the standard criteria for PRRT.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This phase 3 trial tests a radioactive drug (177Lu-DOTATATE) against a long-acting medication (Octreotide LAR) for people with advanced neuroendocrine tumors (NETs) that have grown despite standard treatment. The study aims to see which treatment works better and is safer.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This study follows people with a type of digestive tract cancer called GEP-NET that has spread and is growing. It uses a special imaging scan to find tumors that absorb a radioactive drug, then treats them with targeted radiation therapy. The goal is to learn more about who benefits most from this treatment.
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.